Cytovale's IntelliSep test demonstrates improvements in sepsis care, study shows
A comprehensive study across four hospitals shows that Cytovale's IntelliSep test reduces sepsis mortality by over 19%, improves early detection, and optimizes resource use, leading to better patient outcomes.
Cytovale has revealed results from a multicenter study, validating its IntelliSep test. Findings showed clinical and operational improvements in sepsis care across four hospitals within Franciscan Missionaries of Our Lady (FMOL) Health.
In a one-year pre- and post-implementation analysis of more than 34,000 ED patients with suspected infection, expansion of the IntelliSep rapid host-response sepsis diagnostic beyond the initial site was associated with a 20%+ reduction in mortality and resource utilization.
Cytovale shared the following key findings:
19% relative reduction in sepsis mortality, driven by earlier identification of high-risk patients and faster initiation of life-saving treatment.
22% relative reduction in mortality among patients initially suspected of sepsis who were ultimately not septic. By quickly ruling out sepsis, IntelliSep enabled clinicians to identify and treat the true underlying condition sooner.
20% increase in ED discharges with no increase in seven‑day revisit rates.
30% decrease in blood culture utilization, concentrated among patients ultimately not diagnosed with sepsis, while maintaining greater than 90% utilization among confirmed sepsis patients.
